| Literature DB >> 26190836 |
Kyung-Soo Kim1, Yi-Sun Song2, Jiyong Jin3, Jun-Ho Joe2, Byung-Im So2, Jun-Young Park2, Cheng-Hu Fang3, Mi Jung Kim4, Youl-Hee Cho5, Sejin Hwang6, Young-Suck Ro7, Hyuck Kim8, You-Hern Ahn9, Hak-Joon Sung10, Jung-Joon Sung11, Sung-Hye Park12, Stuart A Lipton13.
Abstract
Effective treatment of diabetic neuropathy (DN) remains unsolved. We serendipitously observed dramatic relief of pain in several patients with painful DN receiving granulocyte-colony stimulating factor (G-CSF). The aim of this study was to determine if G-CSF could treat DN in an animal model and to ascertain its mechanism of action. In a rodent model of DN, G-CSF dramatically recovered nerve function, retarded histological nerve changes and increased the expression of neurotrophic factors within nerve. A sex-mismatched bone marrow transplantation (BMT) study revealed that G-CSF treatment increased the abundance of bone marrow (BM)-derived cells in nerves damaged by DN. However, we did not observe evidence of transdifferentiation or cell fusion of BM-derived cells. The beneficial effects of G-CSF were dependent on the integrity of BM. In conclusion, G-CSF produced a therapeutic effect in a rodent model of DN, which was attributed, at least in part, to the actions of BM-derived cells.Entities:
Keywords: Bone marrow-derived cells; Diabetic neuropathy; Granulocyte-colony stimulating factor
Mesh:
Substances:
Year: 2015 PMID: 26190836 DOI: 10.1016/j.mce.2015.07.014
Source DB: PubMed Journal: Mol Cell Endocrinol ISSN: 0303-7207 Impact factor: 4.102